Modality
Multispecific
MOA
FGFRi
Target
GIP-R
Pathway
Wnt
FL
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Oct 2030
Phase 1Current
NCT08243083
1,437 pts·FL
2021-07→TBD·Active
NCT03735863
2,134 pts·FL
2021-10→2030-10·Terminated
3,571 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-244.6y awayInterim· FL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Active
P1
Termina…
Catalysts
Interim
2030-10-24 · 4.6y away
FL
ActiveTerminated|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |